| Written | 2008-05 | Eileen Friedman |
| Upstate Medical University, State University of New York, Syracuse, New York 13210, USA |
| Identity |
| Other alias | MIRK |
| LocusID (NCBI) | 9149 |
| Atlas_Id | 43235 |
| Location | 19q13.2 [Link to chromosome band 19q13] |
| Location_base_pair | Starts at and ends at bp from pter |
| Fusion genes (updated 2017) | Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands) |
| DYRK1B (19q13.2) / SENP3 (17p13.1) |
| DNA/RNA |
| Description | 11 exons and 10 introns encompassing 8.8kb. |
| Transcription | Start at exon 1 encodes major active form p69, with alternative splicing in exon 9 giving rise to kinase inactive p62, and with alternative splicing within intron 1-2 giving rise to p75 in skeletal muscle. |
| Pseudogene | None reported |
| Protein |
| Note | Serine/threonine kinase activated by intramolecular phosphorylation on tyrosine. |
| Description | 629 amino acids. |
| Expression | Widely expressed at low levels, with elevated expression in muscle and testis. |
| Function | Mediates myoblast differentiation. |
| Mutations |
| Note | None in SW480 colon cancer cells, none reported. |
| Implicated in |
| Note | |
| Entity | Ductal adenocarcinoma of the pancreas |
| Note | Active kinase in pancreatic cancer cell lines. |
| Disease | Present in 89% of cases by immunocytochemistry (25 of 28 cases) |
| Cytogenetics | 19q13 amplicon in 10% of cases |
| Hybrid/Mutated Gene | None reported |
| Abnormal Protein | None reported |
| Oncogenesis | Embryonic knockout is viable and has no reported phenotype |
| Entity | Rhabdomyosarcoma |
| Note | Overexpressed in 12 of 16 cases; active kinase in rhabdomyosarcoma cell lines |
| Breakpoints |
| Note | None reported |
| Bibliography |
| The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma. |
| Deng X, Ewton DZ, Li S, Naqvi A, Mercer SE, Landas S, Friedman E. |
| Cancer Res. 2006 Apr 15;66(8):4149-58. |
| PMID 16618736 |
| The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer. |
| Jin K, Park S, Ewton DZ, Friedman E. |
| Cancer Res. 2007 Aug 1;67(15):7247-55. |
| PMID 17671193 |
| Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells. |
| Lee K, Deng X, Friedman E. |
| Cancer Res. 2000 Jul 1;60(13):3631-7. |
| PMID 10910078 |
| Mirk/Dyrk1b mediates cell survival in rhabdomyosarcomas. |
| Mercer SE, Ewton DZ, Shah S, Naqvi A, Friedman E. |
| Cancer Res. 2006 May 15;66(10):5143-50. |
| PMID 16707437 |
| Citation |
| This paper should be referenced as such : |
| Friedman, E |
| DYRK1B (dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B) |
| Atlas Genet Cytogenet Oncol Haematol. 2009;13(4):263-264. |
| Free journal version : [ pdf ] [ DOI ] |
| On line version : http://AtlasGeneticsOncology.org/Genes/DYRK1BID43235ch19q13.html |
| External links |
| Nomenclature | |
|---|---|
| Cards | |
| Atlas | DYRK1BID43235ch19q13.txt |
| Aliases | |
| Genomic and cartography | |
| Gene and transcription | |
| RefSeq transcript (Entrez) | |
| RefSeq genomic (Entrez) | |
| SOURCE (Princeton) | Expression in : [Datasets] [Normal Tissue Atlas] [carcinoma Classsification] [NCI60] |
| BioGPS (Tissue expression) | 9149 |
| Protein : pattern, domain, 3D structure | |
| Domain families : Pfam (Sanger) | |
| Domain families : Pfam (NCBI) | |
| Protein Interaction databases | |
| Ontologies - Pathways | |
| Clinical trials, drugs, therapy | |
| Miscellaneous | |
| canSAR (ICR) | (select the gene name) |
| Probes | |
| Litterature |
| REVIEW articles | automatic search in PubMed |
| Last year publications | automatic search in PubMed |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Thu Oct 18 17:34:25 CEST 2018 |
For comments and suggestions or contributions, please contact us